Furthermore, our data in a preclinical DCIS model indicated that inhibiting the MEK/ERK pathway could be an effective strategy for intervention of the early-stage breast cancer, and this strategy may potentially be applicable in the clinic. The gene discussed is MAP2K7; the disease is ductal breast carcinoma in situ.